BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19010541)

  • 21. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.
    Fluhr S; Boerries M; Busch H; Symeonidi A; Witte T; Lipka DB; Mücke O; Nöllke P; Krombholz CF; Niemeyer CM; Plass C; Flotho C
    Clin Epigenetics; 2016; 8():50. PubMed ID: 27158276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R.
    Iversen PO; Rodwell RL; Pitcher L; Taylor KM; Lopez AF
    Blood; 1996 Oct; 88(7):2634-9. PubMed ID: 8839857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.
    Emanuel PD; Snyder RC; Wiley T; Gopurala B; Castleberry RP
    Blood; 2000 Jan; 95(2):639-45. PubMed ID: 10627474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.
    Chan RJ; Leedy MB; Munugalavadla V; Voorhorst CS; Li Y; Yu M; Kapur R
    Blood; 2005 May; 105(9):3737-42. PubMed ID: 15644411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
    Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
    Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene.
    Nishioka C; Ikezoe T; Yang J; Yokoyama A
    Leukemia; 2010 Sep; 24(9):1631-40. PubMed ID: 20596030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
    Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
    Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Juvenile myelomonocytic leukemia.
    Satwani P; Kahn J; Dvorak CC
    Pediatr Clin North Am; 2015 Feb; 62(1):95-106. PubMed ID: 25435114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of PTEN promoter methylation in cerebral cavernous malformations.
    Zhu Y; Wloch A; Wu Q; Peters C; Pagenstecher A; Bertalanffy H; Sure U
    Stroke; 2009 Mar; 40(3):820-6. PubMed ID: 19118244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice.
    Iversen PO; Lewis ID; Turczynowicz S; Hasle H; Niemeyer C; Schmiegelow K; Bastiras S; Biondi A; Hughes TP; Lopez AF
    Blood; 1997 Dec; 90(12):4910-7. PubMed ID: 9389708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAS-blocking bisphosphonate zoledronic acid inhibits the abnormal proliferation and differentiation of juvenile myelomonocytic leukemia cells in vitro.
    Ohtsuka Y; Manabe A; Kawasaki H; Hasegawa D; Zaike Y; Watanabe S; Tanizawa T; Nakahata T; Tsuji K
    Blood; 2005 Nov; 106(9):3134-41. PubMed ID: 16046524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of human androgen receptor gene analysis to aid the diagnosis of JMML in female noonan syndrome patients.
    Lavin VA; Hamid R; Patterson J; Alford C; Ho R; Yang E
    Pediatr Blood Cancer; 2008 Aug; 51(2):298-302. PubMed ID: 18454468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
    Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
    Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hallway gossip between Ras and PI3K pathways.
    Emanuel PD
    Blood; 2014 May; 123(18):2751-3. PubMed ID: 24786454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus infection mimicking juvenile myelomonocytic leukemia showing hypersensitivity to granulocyte-macrophage colony stimulating factor.
    Moritake H; Ikeda T; Manabe A; Kamimura S; Nunoi H
    Pediatr Blood Cancer; 2009 Dec; 53(7):1324-6. PubMed ID: 19731324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
    Metzner A; Horstmann MA; Fehse B; Ortmeyer G; Niemeyer CM; Stocking C; Mayr GW; Jücker M
    Gene Ther; 2007 Apr; 14(8):699-703. PubMed ID: 17268534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.